Interferon free therapy with direct acting antivirals for HCV.

Abstract

The current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct-acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG-IFN) plus ribavirin (RBV) regimen. Major progress has been made in the past few years: numerous ongoing trials with different compounds, increasing sustained virological response (SVR) rates with oral regimens and shortened treatment duration. Combinations of antivirals with additive potency that lack cross-resistance and with a good safety profile may provide new regimens in the future to make HCV the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN.

• Authors: Tarik Asselah, Patrick Marcellin
• Journal: Liver international : official journal of the International Association for the Study of the Liver (Liver Int) Vol. 33 Suppl 1 Pg. 93-104 (Feb 2013) ISSN: 1478-3231 [Electronic] United States
• PMID: 23286852 (Publication Type: Journal Article, Review)
• Copyright: © 2012 John Wiley & Sons A/S.

Chemical References

• Antiviral Agents
• Interferon alpha-2
• Interferon-alpha
• NS3 protein, hepatitis C virus
• NS4 protein, hepatitis C virus
• Recombinant Proteins
• Serine Proteinase Inhibitors
• Viral Nonstructural Proteins
• Polyethylene Glycols
• Ribavirin
• NS-5 protein, hepatitis C virus
• peginterferon alfa-2b
• peginterferon alfa-2a

Topics

• Antiviral Agents (adverse effects, chemistry, therapeutic use)
• Drug Design
• Drug Therapy, Combination
• Genotype
• Hepacivirus (drug effects, enzymology, genetics)
• Hepatitis C, Chronic (diagnosis, drug therapy)
• Humans
• Interferon alpha-2
• Interferon-alpha (therapeutic use)
• Models, Molecular
• Molecular Structure
• Polyethylene Glycols (therapeutic use)
• Recombinant Proteins (therapeutic use)
• Ribavirin (therapeutic use)
• Serine Proteinase Inhibitors (adverse effects, chemistry, therapeutic use)
• Treatment Outcome
• Viral Nonstructural Proteins (antagonists & inhibitors)